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Abstract
In humans, clearance of hepatitis C virus (HCV) infection is associated with genetic variation near the IL-28B gene and the
induction of interferon-stimulated genes, like IP-10. Also in chimpanzees spontaneous clearance of HCV is observed. To
study whether similar correlations exist in these animals, a direct comparison of IP-10 and IL-28B polymorphism between
chimpanzees and patients was performed. All chimpanzees studied were monomorphic for the human IL-28B SNPs which
are associated with spontaneous and treatment induced HCV clearance in humans. As a result, these particular SNPs cannot
be used for clinical association studies in chimpanzees. Although these human SNPs were absent in chimpanzees, gene
variation in this region was present however, no correlation was observed between different SNP-genotypes and HCV
outcome. Strikingly, IP-10 levels in chimpanzees correlated with HCV-RNA load and cGT, while such correlations were not
observed in humans. The correlation between IP-10, cGT and virus load in chimpanzees was not found in patients and may
be due to the lack of lifestyle-related confounding factors in chimpanzees. Direct comparison of IP-10 and IL-28B
polymorphism between chimpanzees and patients in relation to HCV infection, illustrates that the IFN-pathways are
important during HCV infection in both species. The Genbank EMBL accession numbers assigned to chimpanzees specific
sequences near the IL-28B gene are HE599784 and HE599785.
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Background
Worldwide, an estimated 170 million people are chronically
infected with the hepatitis C virus (HCV) [1] and are therefore at
risk to develop liver diseases, like cirrhosis and hepatocellular
carcinoma. Upon infection with HCV, only a minority of
individuals can clear the virus spontaneously, while the majority
of patients become chronically infected [2,3]. In recent years, an
important role for host factors has been documented in
determining the progression towards chronicity of HCV as well
as prediction of therapy-induced clearance of HCV [4–10].
Genetic variation on chromosome 19, within an intergenic region
upstream of the IL-28B gene, encoding for the IFN lambda 3
protein (IFNl3) correlates with both spontaneous as well as
treatment-induced clearance [6,8]. Furthermore, low plasma levels
of interferon-gamma-inducible protein 10 (IP-10) prior to therapy
predict treatment-induced clearance of HCV infection [7,11–13]
but whether these two factors interrelate is currently under intense
debate. However, this is highly relevant since both parameters
directly interfere with antiviral IFN-pathways.
Chimpanzees are not only the closest living evolutionary
relatives of humans but also the only validated animal model to
study HCV infection. Similar to humans, HCV in chimpanzees
can either lead to a self-limiting infection or to viral persistence,
and also in the chimpanzee, antigen specific cellular immune
responses are believed to be important [14–16]. In patients, low
pre-treatment IP-10 levels in serum and strong upregulation of
IFN-stimulated genes (ISGs) during treatment in the liver were
shown to correlate with successful IFNa based therapy
[7,9,11,12,17]. However, in contrast to humans, standard IFNa-
based therapy failed to reduce serum HCV RNA levels in
chronically infected chimpanzees [18], and therefore mechanisms
leading to treatment-induced sustained virological response (SVR)
cannot be studied in these animals. The lack of clinical response to
IFNa in chimpanzees was suggested to be similar to that in
patients nonresponsive to therapy: a maximum induction of ISGs
by HCV itself, rather than by treatment with exogenous IFNa
[18].
Interestingly, also a weak association between the preferred IL-
28B genotypes and low serum IP-10 baseline levels in patients
chronically infected with HCV was recently reported [11,19]. This
suggests an interaction between IP-10 and IFNl during the course
of HCV infection in humans [12]. However, at present, a clear
understanding of the mechanisms and their potential role in viral
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clearance is lacking. In this study, we aimed to evaluate and
compare IP-10 and polymorphism near the IL-28B gene in
chimpanzees and humans in relation to HCV infection to obtain
better insight in the potential association between the two host
factors in HCV infection.
We show that, however chimpanzees do not possess the same
human SNPs near the IL-28B gene, allelic variation is present in
this region in chimpanzees. No association was observed between
IL-28B polymorphism and the course of HCV infection in
chimpanzees. Furthermore, we report a positive correlation
between peripheral levels of IP-10 and HCV RNA as well as
cGT levels in chimpanzees, but not in patients. These findings
demonstrate differences between HCV-infected chimpanzees and
patients, which may impact pathophysiologic processes in the liver.
Results
No evidence found for the human SNPs associated with
HCV clearance in chimpanzees
In humans, spontaneous as well as treatment-induced clearance
was found to be associated with a series of SNPs upstream of the
IL-28B gene [4–6,8,10]. To assess whether clearance of HCV in
chimpanzees is associated with the same SNPs, genotype analysis
of chimpanzee DNA was performed for rs8099917 and
rs12979860.
The SNP rs8099917 consistently showed thymidine at this
position on both chromosomes, indicating that all animals tested
were homozygous rs8099917-TT carriers. In humans rs8099917-
T is the preferred allele associated with HCV clearance. In
addition, the chimpanzees were also genotyped for the rs12979860
SNP, and again no evidence was found for variance at this
position. All animals tested had homozygous rs12979860-TT
genotypes. In humans, the rs12979860-T allele is the so-called
risk-allele associated with an increased risk for viral persistence.
Thus, both IL-28B associated human SNPs are not present in
chimpanzees.
Chimpanzees possess a unique sequence near the IL-28B
gene
Since rs8099917 and rs12979860 genotyping was performed by
sequencing, the neighboring nucleotide sequences are also known,
allowing us to compare this region with documented human
genome sequences (National Institutes of Health, Bethesda, USA).
Two different haplotypes were observed near rs12979860,
Figure 1. Correlation between HCV viremia and IP-10 in serum in chimpanzees. Box-whisker plots indicate the interquartile range and the
median (horizontal line) of IP-10 concentrations in serum from animals of the different groups; ‘‘high HCV load’’ where the virus load of individual
animal is higher as compared to median value of 200,000 IU/ml; ‘‘low HCV load’’ where the virus load of individual animal is lower as compared to the
median value of 200,000 IU/ml; HCV resolvers and naı¨ve, non-exposed (A). Box-whisker plots indicate the interquartile range and the median
(horizontal line) of IP-10 concentrations in serum of humans and chimpanzees with high HCV load (.median virus load) and low HCV load (,median
virus load) (B) and IP-10 concentrations plotted against HCV-RNA load in serum from chimpanzees and humans (C). A significant correlation between
the two parameters is defined as r2.0.85 and p,0.05 where ‘‘r2’’ is a measure for correlation and ‘‘p’’ is a measure for the quality if this correlation.
doi:10.1371/journal.pone.0046645.g001
IP-10 and IL-28B in HCV Infected Chimpanzees
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HE599784 and HE599785. Notable was the strong uneven
distribution: 62 out of 63 animals were heterozygous, carrying
both HE599784 and HE599785. Only one animal was found to be
homozygous for HE599785. These data suggest that an as yet
unknown balancing selection may be operative on this region.
No detectable IFNl in serum from chimpanzees
In humans carrying the rs12979860-TT genotype, significant
lower serum levels of IFNl were documented in chronically
infected patients as compared to patients with resolved infections
[19,20]. To investigate whether this difference could also be
observed in chimpanzees, ELISA was performed on sera from
chronically infected animals and animals that cleared the infection.
Using commercially available immunoassays designed to detect
human IL-28A/B and IL-29, we were unable to detect IFNl in
sera from any of the chimpanzees tested, neither in animals
chronically infected with HCV nor animals that spontaneously
cleared the infection. In the same assays, IL-28A/B and IL-29
could be detected in sera from patients with chronic HCV
infection (data not shown; detection limit of the assays: 62.5 pg/ml
and 8 pg/ml, respectively).
IP-10 levels in serum correlate with viral load in HCV
infected chimpanzees, but not in humans
To investigate whether the IP-10 levels in serum were associated
with viral clearance, we compared IP-10 levels of chronically
infected animals with a high HCV load (.200,000 IU/ml), low
HCV load (,200,000 IU/ml), chimpanzees that had resolved
HCV infection early after experimental exposure, and a group of
HCV-naı¨ve, non-exposed chimpanzees. As shown in Figure 1(a),
the IP-10 levels in sera of animals with a high viral load were
significantly higher relative to animals in the other groups. The
serum IP-10 levels of animals with low viremia, animals that
Figure 2. Relation between IP-10 levels and aminotransferases in serum. Relation between IP-10 and liver enzymes cGT, ALT and AST from
HCV-infected individual chimpanzees (A) and HCV-infected patients (B) A significant correlation between the two parameters is defined as r2.0.85
and p,0.05 where ‘‘r2’’ is a measure for correlation and ‘‘p’’ is a measure for the quality if this correlation.
doi:10.1371/journal.pone.0046645.g002
IP-10 and IL-28B in HCV Infected Chimpanzees
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resolved the infection and HCV-naı¨ve animals were relatively low
and comparable between these groups.
Earlier studies in chronically infected patients demonstrated an
association between viral load and IP-10 levels in serum [21,22].
Therefore, we evaluated whether this correlation also existed in
chimpanzees. As shown in Figure 1(b), at a low viral load, the IP-
10 levels were similar in humans and chimpanzees. In contrast,
serum IP-10 levels were higher in chimpanzees with a high viral
load relative to human patients with similar high viral loads. A
strong correlation between serum IP-10 concentration and viral
load was observed in chronically infected chimpanzees. In contrast
to chimpanzees, neither a correlation was observed in the overall
group of patients chronically infected with HCV (Figure 1(c)), nor
when this group was divided into subgroups according to their
rs12979860 genotype (data not shown).
Serum IP-10 concentrations correlate with cGT in HCV
infected chimpanzees, but not in humans
In patients, the concentration of the serum aminotransferase
ALT is used as indicator of active damaging processes in the liver
during chronic HCV infection. However, in chimpanzees, cGT
tends to be more increased rather than ALT. We therefore
assessed whether IP-10 levels in blood correlated with the liver
enzymes cGT, ALT and AST in chronically HCV infected
chimpanzees and patients. As shown in Figure 2(a), in chimpan-
zees the serum levels of IP-10 strongly correlated with cGT
(r2 = 0.91 and p,0.0001), while no correlation was observed
between IP-10 and either ALT (r2 = 0.58; p = 0.0007) or AST
(r2 = 0.17; p = 0.11). In contrast, in HCV infected patients, no
correlations were observed between serum IP-10 and the
aminotransferases (Figure 2(b)). Direct comparison of the levels
of ALT and AST in serum of patients and chimpanzees
demonstrated that only moderate ALT values were observed in
chimpanzees, whereas 4 out of 58 patients exceeded an ALT value
of 200 U/ml which is more then 4 times the maximum reference
value for healthy humans and chimpanzees (Figure 3). Similarly,
also AST levels were only moderately increased in chimpanzees,
whereas 11 patients exceeded the maximum reference value by
threefold. In contrast, serum cGT levels were found to be
substantially elevated in some individuals from both species: in 3
out of 16 chimpanzees and 7 out of 60 patients, the cGT levels
exceeded 200 U/ml, which is more then 5 times its reference value
in healthy humans and chimpanzees.
Discussion
In humans, HCV clearance is associated with specific IL-28B
gene polymorphisms as well as the levels of specific ISG, such as
IP-10 [4,5,7,8,10,13]. It has been suggested that these pathways
are associated with one another in humans [11,19] although the
interrelating mechanism is still unknown. The work presented here
was designed to assess whether a potential correlation between
IFNl and polymorphism near the IL-28B gene can be studied in
chimpanzees.
In humans, genetic variation near the IL-28B gene is associated
with spontaneous as well as treatment-induced clearance of HCV
[4,5,8,10]. In chimpanzees, we found no evidence for these human
SNPs and therefore it is unlikely that these specific SNPs play a
role during HCV infection in chimpanzees. Instead, all animals
tested were found to be homozygous carriers for rs12979860-TT
and rs8099917-TT, which is in line with recently reported data on
chimpanzees from another primate center [23]. A potential
explanation may be that HCV is regarded as a human disease
as no documentation is available on wild chimpanzees infected
with HCV. In that respect different evolutionary selective pressure
may have caused differences in innate responses between both
species.
Since the documented SNPs, rs12979860 and rs8099917 are
located in an intergenic region rather than within gene-encoding
regions of the DNA, there may be a link between the region where
the SNPs are located and another, yet unspecified gene. Given the
fact that humans and chimpanzees share a common ancestor, the
chimpanzee sequence likely represents the ancestral genotypes.
This is in line with the finding that Central and Western African
human populations carry the rs12979860-TT genotype at high
frequency [10].
Even though humans and chimpanzees show 98.8% identity at
the DNA level [24], many SNPs identified in humans are not
necessarily present in chimpanzees. Although no evidence was
found in chimpanzees for the two SNPs with documented
Figure 3. cGT, ALT and AST in humans and chimpanzees
chronically infected with HCV. Interquartile range and the median
(horizontal line) of cGT, ALT and AST in U/ml in chimpanzees and
patients chronically infected with HCV.
doi:10.1371/journal.pone.0046645.g003
IP-10 and IL-28B in HCV Infected Chimpanzees
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relevance during HCV infection in humans, additional polymor-
phism near the IL-28B gene was detected. In the animals tested, a
remarkable level of heterozygous carriers was observed, which
may suggest a balancing selection being operative on this region.
Our findings cannot be explained by the breeding strategy as
concluded on the basis of variation in the mtDNA [25], and
because it was also observed in animals from outside the BPRC
breeding colony. The underlying mechanism responsible for this
heterogeneity to assure a genetically diverse population is
unknown.
In serum from chimpanzees no IFNl was detected, and
therefore no conclusion could be drawn from its effect on the
outcome of HCV infection in chimpanzees. IFNl has been
measured in chimpanzees before using human detection reagents
[23]. Given the rapid normalization of IFNl levels in chimpanzees
shortly after infection, it is expected that IFNl is too low to detect
during the chronic phase of infection. Lower IFNl levels in
chimpanzees could not be explained by a different copy number of
the IFNl-encoding genes as both in humans as well as
chimpanzees only one copy of each of the IL-29/IL28A and IL-
28B genes was observed (human and chimpanzee database
supported by National Institutes of Health, Bethesda, USA).
In patients chronically infected with HCV, low baseline IP-10
levels are predictive for successful treatment-induced clearance [7].
Our data show that IP-10 levels are higher in chronically infected
chimpanzees relative to patients. This finding is in line with the
suggestion that HCV infection causes stronger upregulation of
ISGs in chimpanzees as compared to humans [18]. Furthermore,
based on data from a limited number of animals with high HCV-
RNA levels, it was suggested that the failure of chimpanzees to
respond successfully to IFN-based antiviral treatment was due to
high baseline activation of the IFN-system. Based on our data it is
to be expected that peripheral IP-10 levels from the animals in the
Lanford-study are high. Given the documented correlation
between high IP-10 and limited treatment success in humans, it
is tempting to speculate that chimpanzees with a high HCV load
and subsequently high baseline IP-10 levels in serum are indeed
equivalent to human non-responders to IFN-based therapy.
However, this implies that animals with lower IP-10 may respond
to IFN-based therapy.
As humans and chimpanzees do not to show the same variation
near the IL-28B gene, we were not able to confirm the earlier
documented association between IL-28B variation and cGT levels
in humans [17]. We did however find a correlation between cGT,
IP-10 and virus load. This may imply, interrelating mechanisms
play a role in both humans and chimpanzees, but that species-
specific factors may contribute to biochemical differences between
both species.
Conclusion
Our data show that although chimpanzees do not possess the
SNP near the IL-28B gene that are associated with HCV outcome
in humans, chimpanzees do show genetic variation in this region.
Furthermore, we found a positive correlation between IP-10 and
viral load as well as cGT in chimpanzees, which was not found in
patients. This difference may reflect the heterogeneous character-
istics of HCV induced reactions in the liver of both species. The
correlation between IP-10, virus load and cGT may reflect the
lack of confounding factors in chimpanzees, since heavy alcohol
intake, diabetes and obesity are known to influence the progression
of HCV infection in humans, but not in chimpanzees.
Methods
Study population
To study the potential roles of IP-10 and polymorphisms during
HCV infection in chimpanzees, we examined these parameters
using the unique repository of chimpanzee DNA and serum
samples of the Biomedical Primate Research Centre (BPRC). This
database contains surplus material from blood samples collected
routine health check purposes by both the BPRC as well as third
party owners of chimpanzees. The work described here, was
Table 1. Characteristics of chimpanzee population.
High viral load Low viral load Cleared HCV Naive animals
n 8 6 6 10
genotype 1 1 1
years p.i. 4 (4–21) 3 (2–4) 4.5 (3–10)
HCV RNA (IU/ml) 505,000 (207,000–1,080,000) 31,908 (649–95,500) 0 0
IP-10 (pg/ml) 2247 (547–5956) 274 (209–359) 143 (71–131) 414 (146–1834)
ALT (U/ml) 91 (39–162) 58 (46–82)
AST (U/ml) 34 (20–54) 33 (18–46)
cGT (U/ml) 204 (30–558) 33 (20–55)
Characteristics of the chimpanzee population studied, the HCV-genotype, the time since HCV exposure, HCV-RNA load, serum IP-10levels, and the liver enzymes levels
ALT, AST and cGT. The average values and the range are shown.
doi:10.1371/journal.pone.0046645.t001
Table 2. Characteristics of the patient cohort chronically
infected with HCV.
High viral load Low viral load
n 30 27
genotype 1/2/3/6 1/3/4
HCV RNA (IU/ml) 7,827,576 (585,185–
42,100,000)
255,115 (15– 2,114,180)
IP-10 (pg/ml) 540 (67–2000) 281 (66–902)
ALT (U/ml) 135 (17–444) 84 (20–263)
AST (U/ml) 80 (25–251) 64 (24–255)
cGT (U/ml) 87 (16–347) 70 (9–205)
Characteristics of chronic HCV patients studied: HCV genotype, HCV-RNA load,
serum IP-10 levels, the levels of liver enzymes ALT, AST and cGT. The average
values and the range are presented.
doi:10.1371/journal.pone.0046645.t002
IP-10 and IL-28B in HCV Infected Chimpanzees
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designed around the availability of the samples thus, no samples
were collected from chimpanzees for the purpose of this work.
Table 1 summarizes the relevant characteristics of the chimpanzee
cohort included in this study. The animals were divided into
different groups based on their HCV status: 1) ‘‘high viral load’’:
animals who were experimentally infected with HCV and virus
load consistently higher than 200,000 IU/ml, where 200,000 is
the median virus load of the animals in the study; 2) ‘‘low viral
load’’: animals who were experimentally infected with HCV and
viral load consistently lower than 200,000 IU/ml; 3) ‘‘cleared’’:
animals who were experimentally infected with HCV and resolved
infection 4) ‘‘naive‘‘: non–infected animals that serve as healthy
controls. In addition, DNA samples of 44 animals were screened
for the presence of genetic variation near the IL28B gene. In total
63 chimpanzees were included in the analysis of the IL-28B region
of which 11 animals were not part of the BPRC breeding.
Blood samples were obtained from patients with chronic HCV
infection visiting the outpatient clinic of the Erasmus Medical
Center (see Table 2). Patients were infected with either HCV
genotype 1 (n = 37), genotype 2 (n = 3), genotype 3 (n = 13),
genotype 4 (n = 4) or genotype 6 (n = 1). Patients co-infected with
human immunodeficiency virus, hepatitis A virus, hepatitis B virus
or hepatitis D virus were excluded from the study. The protocol
was approved by the Medical Ethics Committee of the Erasmus
Medical Center and all patients gave their written informed
consent. In line with the chimpanzee cohort, the patients were
divided into different groups based on their HCV status: 1) ‘‘high
virus load’’: virus load consistently higher than 500,000 IU/ml,
where 500,000 is the median virus load of all patients in this study;
2) ‘‘low virus load’’: patients with virus load consistently lower than
500,000 IU/ml.
Determination of HCV load and liver enzymes
Quantification of HCV RNA levels was assessed using the
Cobas Amplicor HCV monitor test (Roche Diagnostics, Branch-
burg) according to the instructions of the manufacturer. The levels
of cGT, ALT and AST were determined in serum using the
COBAS Integra 400 plus analysis system.
IL-28B gene associated polymorphisms in chimpanzees
To determine the genotype of the rs8099917 and rs12979860,
genomic DNA was isolated from either chimpanzee PBMC or
whole blood [26] and the nucleotide sequence was determined by
PCR amplification followed by direct sequencing. To assess the
genotype of rs8099917, a previously described set of PCR primers
was used [27], while a new set of primers was designed for the
amplification of a fragment of 209 bp containing rs12979860 (IL-
28-860-F2 59-GGACAAGCGGCGCTTATCG-39 and IL-28-
860-R2 59-GGCTCCAGGTCGGG GCG-39). To amplify the
fragments of interest, 1 mg of genomic DNA, 0.5 mM of each PCR
primer, 0.2 mM dNTP each, 1.5 mM MgCl2 and 1 unit of
Platinum Taq DNA polymerase (Invitrogen, Paisley, Scotland)
were mixed in the appropriate PCR buffer in a total volume of
50 ml. The PCR conditions were: 1 cycle of denaturation at 94uC
for 2 min, 30 cycles of denaturation at 94uC for 30 s, annealing at
61uC for 30 s and extension of 68uC for 30 s, followed by a final
extension for 7 min at 68uC. PCR fragments were purified, using
the GenJETTM Gel Extraction Kit (Fermentas, St. Leon-Rot,
Germany) according to the manufacturer’s protocol. The nucle-
otide sequence of the PCR fragments was determined using the
ABI Prism BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, USA). 0.2 mM of PCR primer,
1 ml of BigDye Terminator-mix and 56sequencing dilution buffer
in a total volume of 10 ml and sequenced directly on an ABI
3130XL genetic analyzer (Applied Biosystems, Foster City, USA).
The data was analyzed using MacVectorTM version 12.0.2
(MacVector, Inc Cambridge, UK). Sequences observed for
rs12979860 were deposited in the EMBL database and received
the accession numbers HE599784 and HE599785.
The genotypes of the IL28B associated SNPs in blood of
patients were determined using competitive allele-specific PCR
(KASP; Kbioscience Hoddesdon, UK).
Serum levels of IP-10, IL-29 and IL-28A/B
The concentrations of IP-10, IL-29 and IL-28A/B in serum
were determined using commercially available kits. The levels of
IP-10 in patient- and chimpanzee sera were measured using the
Quantikine Kit (R&D Systems, Abingdon, UK; sensitivity of assay:
2 pg/ml). The concentration of IL-29 and IL-28A/B in
chimpanzee sera was measured using VeriKine-DIY Human
Interferon Lambda immunoassays specific for IL-29 or for the
combination of IL-28A/B (both from PBL InterferonSource, NY,
USA). The assays were performed according to the manufacturer’s
instructions, and the detection limits for both immunoassays were
62.5 pg/ml. IL-29 ELISA results were confirmed by the human
IL-29 ELISA Ready-SET-Go! kit (e-Bioscience, San Diego, USA,
detection limit for this assay was 8 pg/ml).
Statistics
Statistical analysis was performed using Graphpad Prism 5.0
(GraphPad Software, Inc., La Jolla, USA). To test if a significant
correlation exists between two quantitative variables, the correla-
tion coefficient r2 is calculated as a measure of variation of 2
variables. In addition, to test whether this correlation was
significant, a t-test was performed. A two tailed T-test was used
to determine statistical difference of liver-enzymes between
patients and chimpanzees.
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